Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03713593
Title Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

hepatocellular carcinoma

Therapies

Lenvatinib

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.